CervoMed Inc. Files 8-K: Regulation FD & Financials

TL;DR

CervoMed dropped an 8-K with Reg FD and financials – check it out.

AI Summary

CervoMed Inc. filed an 8-K on April 4, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Diffusion Pharmaceuticals Inc., RestorGenex Corp, and Stratus Media Group, Inc., is incorporated in Delaware and headquartered in Boston, MA.

Why It Matters

This filing provides important updates on CervoMed's regulatory disclosures and financial reporting, which are crucial for investors to assess the company's current standing.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K for disclosures and exhibits, not indicating any immediate operational or financial distress.

Key Players & Entities

• CervoMed Inc. (company) — Registrant
• Diffusion Pharmaceuticals Inc. (company) — Former company name
• RestorGenex Corp (company) — Former company name
• Stratus Media Group, Inc (company) — Former company name
• April 4, 2024 (date) — Date of report

FAQ

Key Financial Figures

• $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market

Filing Documents

• crvo20240403_8k.htm (8-K) — 30KB
• 0001437749-24-010998.txt ( ) — 159KB
• crvo-20240404.xsd (EX-101.SCH) — 3KB
• crvo-20240404_def.xml (EX-101.DEF) — 11KB
• crvo-20240404_lab.xml (EX-101.LAB) — 15KB
• crvo-20240404_pre.xml (EX-101.PRE) — 11KB
• crvo20240403_8k_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure Corporate Presentations Certain information concerning the business, clinical studies, development plans, financial position and related matters of CervoMed Inc. (the "Company" or "us") has been made available on our website, www.cervomed.com, under the heading, "Investors – Events and Presentations." Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others. The information contained in the presentation is summary information that is intended to be considered in the context of the Company's filings with the Securities and Exchange Commission ("SEC") and other public announcements that we may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01 (including any information incorporated herein by reference) is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of Section 18 of the Exchange Act unless we specifically incorporate it by reference in a document filed under the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 19

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 4, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: General Counsel 3

View Full Filing

View this 8-K filing on SEC EDGAR